dc.contributor.author | González Martínez, Alicia | |
dc.contributor.author | Guerrero Peral, Angel Luis | |
dc.contributor.author | Arias Rivas, Susana | |
dc.contributor.author | Silva, Lorenzo | |
dc.contributor.author | Sierra, Álvaro | |
dc.contributor.author | Gago Veiga, Ana Beatriz | |
dc.contributor.author | García Azorín, David | |
dc.date.accessioned | 2022-08-17T08:30:34Z | |
dc.date.available | 2022-08-17T08:30:34Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Journal of Neurology, 2022. | es |
dc.identifier.issn | 0340-5354 | es |
dc.identifier.uri | https://uvadoc.uva.es/handle/10324/54400 | |
dc.description | Producción Científica | es |
dc.description.abstract | Background Headache is one of the most frequently reported symptoms in post-COVID patients. The clinical phenotype of COVID-19 headache combines phenotypic features of both tension-type headache (TTH) and migraine. We aimed to assess the efectiveness, side efects and predictors of amitriptyline (AMT) response in a real-world study setting. Methods We performed an observational multicentric study with a retrospective cohort. All consecutive patients with con frmed COVID-19 infection who received AMT for post-COVID headache from March 2020 to May 2021 were included. Response was evaluated by the reduction in the number of headache days per month (HDM) between weeks 8 and 12, compared with the baseline. We explored which variables were associated with a higher probability of response to AMT. Results Forty-eight patients were eligible for the study, 40/48 (83.3%) females, aged 46.85 (SD: 13.59) years. Patients had history of migraine 15/48 (31.3%) or TTH 5/48 (10.4%). The mean reduction of HDM was 9.6 (SD: 10.9; 95% CI 6.5, 12.7) days. Only 2/48 (5%) of patients discontinued AMT due to poor tolerability. History of TTH (10.9, 95% CI 1.3, 20.6) and nausea (−8.5, 95% CI −14.6, −2.5) were associated with AMT response. Conclusions This study provides real-world evidence of the potential beneft of AMT in patients with post-COVID-19 headache, especially in patients with history of TTH and without concomitant nausea. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Springer | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.classification | Migraine | es |
dc.subject.classification | Amitriptyline | es |
dc.subject.classification | COVID-19 | es |
dc.subject.classification | Tension-type headache | es |
dc.subject.classification | Long-haulers | es |
dc.title | Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | © 2022 The Authors | es |
dc.identifier.doi | 10.1007/s00415-022-11225-5 | es |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s00415-022-11225-5 | es |
dc.identifier.publicationtitle | Journal of Neurology | es |
dc.peerreviewed | SI | es |
dc.description.project | Ministerio de Economía y Competitividad (Instituto de Salud Carlos III) & Unión Europea (Fondo Social Europeo, FSE+) a través del Río Hortega Beca (CM21/00178) | es |
dc.description.project | Publicación en abierto financiada por el Consorcio de Bibliotecas Universitarias de Castilla y León (BUCLE), con cargo al Programa Operativo 2014ES16RFOP009 FEDER 2014-2020 DE CASTILLA Y LEÓN, Actuación:20007-CL - Apoyo Consorcio BUCLE | es |
dc.identifier.essn | 1432-1459 | es |
dc.rights | Atribución 4.0 Internacional | * |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es |
dc.subject.unesco | 32 Ciencias Médicas | es |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional